A novel derivative of quinazoline, WYK431 induces G2/M phase arrest and apoptosis in human gastric cancer BGC823 cells through the PI3K/Akt pathway

Wang,Tian-En; Wang,Yong-Kang; Jin,Jing; Xu,Bai-Ling; Chen,Xiao-Guang

doi:10.3892/ijo.2014.2458

A novel derivative of quinazoline, WYK431 induces G2/M phase arrest and apoptosis in human gastric cancer BGC823 cells through the PI3K/Akt pathway

Authors:
- Tian-En Wang
- Yong-Kang Wang
- Jing Jin
- Bai-Ling Xu
- Xiao-Guang Chen
View Affiliations

Affiliations: Department of Pharmacology, State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, P.R. China
Published online on: May 22, 2014 https://doi.org/10.3892/ijo.2014.2458
Pages: 771-781

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

WYK431, a novel synthetic quinazoline derivative, showing potent inhibition of proliferation activity against a broad spectrum of human cancer cell lines. We investigated the anticancer effects of WYK431 on BGC823 cells both in vitro and in vivo. The results showed that WYK431 inhibited proliferation, arrested the cell cycle at the G2/M phase, which was related to CDK1 and CDC25C, and induced apoptosis associated with activation of caspase-3 and caspase-9 rather than caspase-8 in BGC823 cells. Treatment of BGC823 cells with WYK431 resulted in upregulation of Bax, release of cytochrome c from the mitochondria to the cytosol and disruption of mitochondrial membrane potential. Western blot analysis showed that WYK431 downregulated the levels of the PI3K/Akt signaling pathway. Moreover, WYK431 effectively suppressed tumor growth in xenograft models in BALB/c athymic nude mice without major side action. TUNEL analysis showed that WYK431 induced BGC823 cell apoptosis in vivo. Collectively, WYK431 is a novel small molecule agent which inhibits BGC823 cell proliferation inducing G2/M phase arrest and apoptosis via the mitochondrial apoptotic pathway. To assess its potential as a promising anticancer agent requires further investigation.

View Figures

View References

1	Kamangar F, Dores GM and Anderson WF: Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 24:2137–2150. 2006. View Article : Google Scholar
2	Crew KD and Neugut AI: Epidemiology of gastric cancer. World J Gastroenterol. 12:354–362. 2006.
3	Wagner AD, Grothe W, Behl S, et al: Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2:CD0040642005.
4	Van Cutsem E, Moiseyenko VM, Tjulandin S, et al: Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 24:4991–4997. 2006.
5	Vivanco I and Sawyers CL: The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2:489–501. 2002. View Article : Google Scholar : PubMed/NCBI
6	Vanhaesebroeck B, Guillermet-Guibert J, Graupera M and Bilanges B: The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol. 11:329–341. 2010. View Article : Google Scholar : PubMed/NCBI
7	Paweletz CP, Charboneau L, Bichsel VE, et al: Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene. 20:1981–1989. 2001. View Article : Google Scholar : PubMed/NCBI
8	Bellacosa A, Kumar CC, Di Cristofano A and Testa JR: Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv Cancer Res. 94:29–86. 2005. View Article : Google Scholar
9	Testa JR and Bellacosa A: AKT plays a central role in tumorigenesis. Proc Natl Acad Sci USA. 98:10983–10985. 2001. View Article : Google Scholar : PubMed/NCBI
10	Liu P, Cheng H, Roberts TM and Zhao JJ: Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 8:627–644. 2009. View Article : Google Scholar : PubMed/NCBI
11	Engelman JA, Luo J and Cantley LC: The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet. 7:606–619. 2006. View Article : Google Scholar : PubMed/NCBI
12	Cantley LC: The phosphoinositide 3-kinase pathway. Science. 296:1655–1657. 2002. View Article : Google Scholar : PubMed/NCBI
13	Lee JW, Soung YH, Kim SY, et al: PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene. 24:1477–1480. 2005. View Article : Google Scholar : PubMed/NCBI
14	Campbell IG, Russell SE, Choong DY, et al: Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res. 64:7678–7681. 2004. View Article : Google Scholar : PubMed/NCBI
15	Li VS, Wong CW, Chan TL, et al: Mutations of PIK3CA in gastric adenocarcinoma. BMC Cancer. 5:292005. View Article : Google Scholar : PubMed/NCBI
16	Bachman KE, Argani P, Samuels Y, et al: The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther. 3:772–775. 2004. View Article : Google Scholar : PubMed/NCBI
17	Duronio V, Scheid MP and Ettinger S: Downstream signalling events regulated by phosphatidylinositol 3-kinase activity. Cell Signal. 10:233–239. 1998. View Article : Google Scholar : PubMed/NCBI
18	Blume-Jensen P and Hunter T: Oncogenic kinase signalling. Nature. 411:355–365. 2001. View Article : Google Scholar : PubMed/NCBI
19	Johnson DG and Walker CL: Cyclins and cell cycle checkpoints. Annu Rev Pharmacol Toxicol. 39:295–312. 1999. View Article : Google Scholar : PubMed/NCBI
20	Senderowicz AM and Sausville EA: Preclinical and clinical development of cyclin-dependent kinase modulators. J Natl Cancer Inst. 92:376–387. 2000. View Article : Google Scholar : PubMed/NCBI
21	Kasibhatla S and Tseng B: Why target apoptosis in cancer treatment? Mol Cancer Ther. 2:573–580. 2003.PubMed/NCBI
22	Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2008. CA Cancer J Clin. 58:71–96. 2008. View Article : Google Scholar
23	Plenchette S, Filomenko R, Logette E, et al: Analyzing markers of apoptosis in vitro. Methods Mol Biol. 281:313–331. 2004.PubMed/NCBI
24	Hengartner MO: The biochemistry of apoptosis. Nature. 407:770–776. 2000. View Article : Google Scholar : PubMed/NCBI
25	Sartorius U, Schmitz I and Krammer PH: Molecular mechanisms of death-receptor-mediated apoptosis. Chembiochem. 2:20–29. 2001. View Article : Google Scholar : PubMed/NCBI
26	Jiang X and Wang X: Cytochrome c promotes caspase-9 activation by inducing nucleotide binding to Apaf-1. J Biol Chem. 275:31199–31203. 2000. View Article : Google Scholar : PubMed/NCBI
27	Wakeling AE, Guy SP, Woodburn JR, et al: ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res. 62:5749–5754. 2002.PubMed/NCBI
28	Baba A, Kawamura N, Makino H, Ohta Y, Taketomi S and Sohda T: Studies on disease-modifying antirheumatic drugs: synthesis of novel quinoline and quinazoline derivatives and their anti-inflammatory effect. J Med Chem. 39:5176–5182. 1996. View Article : Google Scholar : PubMed/NCBI
29	Rohini R, Muralidhar Reddy P, Shanker K, Hu A and Ravinder V: Antimicrobial study of newly synthesized 6-substituted indolo[1,2-c]quinazolines. Eur J Med Chem. 45:1200–1205. 2010.PubMed/NCBI
30	Honkanen E, Pippuri A, Kairisalo P, Nore P, Karppanen H and Paakkari I: Synthesis and antihypertensive activity of some new quinazoline derivatives. J Med Chem. 26:1433–1438. 1983. View Article : Google Scholar : PubMed/NCBI
31	Jin J, Zhu L-N, Zhang H-J, et al: XLN306 induces apoptosis in human breast carcinoma MX-1 cells. Acta Pharm Sin B. 1:84–88. 2011. View Article : Google Scholar
32	Wang YK, Jin J, Zhu LN, et al: Synthesis and antitumor activity of novel 2-(1-substituted-piperidin-4-ylamino)quinazolines as antitumor agents. Yao Xue Xue Bao. 47:1164–1178. 2012.PubMed/NCBI
33	Scaduto RC Jr and Grotyohann LW: Measurement of mitochondrial membrane potential using fluorescent rhodamine derivatives. Biophys J. 76:469–477. 1999. View Article : Google Scholar : PubMed/NCBI
34	Konopleva M, Contractor R, Tsao T, et al: Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell. 10:375–388. 2006. View Article : Google Scholar : PubMed/NCBI
35	Lewis JS, Meeke K, Osipo C, et al: Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation. J Natl Cancer Inst. 97:1746–1759. 2005. View Article : Google Scholar : PubMed/NCBI
36	Nunez G, Benedict MA, Hu Y and Inohara N: Caspases: the proteases of the apoptotic pathway. Oncogene. 17:3237–3245. 1998. View Article : Google Scholar : PubMed/NCBI
37	Green DR and Reed JC: Mitochondria and apoptosis. Science. 281:1309–1312. 1998. View Article : Google Scholar
38	Cubedo E, Cordeu L, Bandres E, et al: New symmetrical quinazoline derivatives selectively induce apoptosis in human cancer cells. Cancer Biol Ther. 5:850–859. 2006. View Article : Google Scholar : PubMed/NCBI
39	Hanahan D and Weinberg RA: Hallmarks of cancer: the next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
40	Shapiro GI and Harper JW: Anticancer drug targets: cell cycle and checkpoint control. J Clin Invest. 104:1645–1653. 1999. View Article : Google Scholar : PubMed/NCBI
41	von Bergwelt-Baildon MS, Kondo E, Klein-Gonzalez N and Wendtner CM: The cyclins: a family of widely expressed tumor antigens? Expert Rev Vaccines. 10:389–395. 2011.PubMed/NCBI
42	Goss VL, Cross JV, Ma K, Qian Y, Mola PW and Templeton DJ: SAPK/JNK regulates cdc2/cyclin B kinase through phosphorylation and inhibition of cdc25c. Cell Signal. 15:709–718. 2003. View Article : Google Scholar : PubMed/NCBI
43	Karlsson-Rosenthal C and Millar JB: Cdc25: mechanisms of checkpoint inhibition and recovery. Trends Cell Biol. 16:285–292. 2006. View Article : Google Scholar : PubMed/NCBI
44	Galea CA, Wang Y, Sivakolundu SG and Kriwacki RW: Regulation of cell division by intrinsically unstructured proteins: intrinsic flexibility, modularity, and signaling conduits. Biochemistry. 47:7598–7609. 2008. View Article : Google Scholar : PubMed/NCBI
45	Chang F, Lee JT, Navolanic PM, et al: Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia. 17:590–603. 2003. View Article : Google Scholar : PubMed/NCBI
46	Wang J, Wu A, Xu Y, Liu J and Qian X: M(2)-A induces apoptosis and G(2)-M arrest via inhibiting PI3K/Akt pathway in HL60 cells. Cancer Lett. 283:193–202. 2009. View Article : Google Scholar : PubMed/NCBI
47	Yuan Q, Cai S, Zhang X, et al: A new protoapigenone analog RY10-4 induces apoptosis and suppresses invasion through the PI3K/Akt pathway in human breast cancer. Cancer Lett. 324:210–220. 2012. View Article : Google Scholar : PubMed/NCBI
48	Li Y, Zhang P, Qiu F, et al: Inactivation of PI3K/Akt signaling mediates proliferation inhibition and G₂/M phase arrest induced by andrographolide in human glioblastoma cells. Life Sci. 90:962–967. 2012. View Article : Google Scholar : PubMed/NCBI
49	Xu YZ, Zheng RL, Zhou Y, et al: Small molecular anticancer agent SKLB703 induces apoptosis in human hepatocellular carcinoma cells via the mitochondrial apoptotic pathway in vitro and inhibits tumor growth in vivo. Cancer Lett. 313:44–53. 2011. View Article : Google Scholar
50	Sun B, Geng S, Huang X, et al: Coleusin factor exerts cytotoxic activity by inducing G₀/G₁ cell cycle arrest and apoptosis in human gastric cancer BGC-823 cells. Cancer Lett. 301:95–105. 2011. View Article : Google Scholar : PubMed/NCBI
51	Ferreira CG, Epping M, Kruyt FA and Giaccone G: Apoptosis: target of cancer therapy. Clin Cancer Res. 8:2024–2034. 2002.PubMed/NCBI
52	Adams JM and Cory S: The Bcl-2 protein family: arbiters of cell survival. Science. 281:1322–1326. 1998. View Article : Google Scholar : PubMed/NCBI
53	Youle RJ and Strasser A: The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol. 9:47–59. 2008. View Article : Google Scholar : PubMed/NCBI
54	Brognard J, Clark AS, Ni Y and Dennis PA: Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res. 61:3986–3997. 2001.PubMed/NCBI
55	Martelli AM, Tazzari PL, Tabellini G, et al: A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cells. Leukemia. 17:1794–1805. 2003. View Article : Google Scholar
56	Hussain AR, Al-Rasheed M, Manogaran PS, et al: Curcumin induces apoptosis via inhibition of PI3’-kinase/AKT pathway in acute T cell leukemias. Apoptosis. 11:245–254. 2006.PubMed/NCBI